{
    "nct_id": "NCT05139602",
    "official_title": "A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab (ABT-981) in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy: Amended Protocol to Include a Lutikizumab Open-Label Sub-study in Subjects Naïve to Biologic Therapy",
    "inclusion_criteria": "* A clinical diagnosis of hidradenitis suppurativa (HS) for at least 1 year prior to Baseline as determined by the investigator.\n* A total abscess and inflammatory nodule (AN) count of >= 5 at Baseline\n* HS lesions must be present in at least 2 distinct anatomic areas.\n* Must have failed anti-TNF treatment for HS.\n* To be eligible for the Sub-study, participants must be naïve to biologic therapy for treatment of HS.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "- History of active skin disease other than HS that could interfere with the assessment of HS, including skin infections (e.g., bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline visit.",
    "miscellaneous_criteria": ""
}